BIOMAT Database Logo BIOMAT Database Logo

Plasma hyaluronidase activity as an indicator of atherosclerosis in patients with coronary artery disease. 2009

Mine Kucur, and Bilgehan Karadag, and Ferruh K Isman, and Yusup Ataev, and Dursun Duman, and Nalan Karadag, and Zeki Ongen, and Vural A Vural
Istanbul University, Fikret Biyal Research Laboratory, Cerrahpasa School of Medicine, Istanbul, Turkey.

OBJECTIVE Recent information has highlightened the impact of HA metabolism alterations in vascular permeability through its actions on endothelial glycocalyx and the importance of HA-cell interactions in cell behavior of arterial endothelial and smooth muscle cells. Therefore hyaluronan is thought to involve in pathophysiology of atherosclerosis. The aim of this study is to investigate the association of plasma hyaluronidase activity with atherosclerosis in non-diabetic patients with stable coronary artery disease. METHODS In the present study we used plasma hyaluronidase measurement as an indicator of hyaluronan metabolism and activity. A total of 162 subjects undergoing to coronary angiography were divided into two groups according to presence or absence of coronary artery disease, and their serum hyaluronidase activity were measured. RESULTS Serum hyaluronidase activities were 3797+/-670.62 mU/L and 2838+/-417.67 mU/L for patients with CAD (n:109) and control patients without CAD (n:53), respectively. Serum hyaluronidase activity in patients with coronary artery disease (CAD) were significantly higher than control subjects without CAD (p<0.001). CONCLUSIONS In the present study hyaluronidase activity was found to be associated with coronary artery disease reflecting the role of hyaluronan in atherosclerosis. We believe that the demonstration of relationship between serum hyaluronidase activity and atherosclerosis represents a remarkable finding highlighting the potential role of hyaluronan in pathophysiology of atherosclerosis (Tab. 2, Fig. 3, Ref. 28). Full Text (Free, PDF) www.bmj.sk.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002097 C-Reactive Protein A plasma protein that circulates in increased amounts during inflammation and after tissue damage. C-Reactive Protein measured by more sensitive methods often for coronary heart disease risk assessment is referred to as High Sensitivity C-Reactive Protein (hs-CRP). High Sensitivity C-Reactive Protein,hs-CRP,hsCRP,C Reactive Protein,High Sensitivity C Reactive Protein
D003324 Coronary Artery Disease Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause. Arteriosclerosis, Coronary,Atherosclerosis, Coronary,Coronary Arteriosclerosis,Coronary Atherosclerosis,Left Main Coronary Artery Disease,Left Main Coronary Disease,Left Main Disease,Arterioscleroses, Coronary,Artery Disease, Coronary,Artery Diseases, Coronary,Atheroscleroses, Coronary,Coronary Arterioscleroses,Coronary Artery Diseases,Coronary Atheroscleroses,Left Main Diseases
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006821 Hyaluronoglucosaminidase An enzyme that catalyzes the random hydrolysis of 1,4-linkages between N-acetyl-beta-D-glucosamine and D-glucuronate residues in hyaluronate. (From Enzyme Nomenclature, 1992) There has been use as ANTINEOPLASTIC AGENTS to limit NEOPLASM METASTASIS. Hyaluronidase,Duran-Reynals Permeability Factor,GL Enzyme,Hyaglosidase,Hyaluronate Hydrolase,Wydase,Duran Reynals Permeability Factor,Factor, Duran-Reynals Permeability,Hydrolase, Hyaluronate,Permeability Factor, Duran-Reynals
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D050197 Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA. Atherogenesis,Atherogeneses,Atheroscleroses

Related Publications

Mine Kucur, and Bilgehan Karadag, and Ferruh K Isman, and Yusup Ataev, and Dursun Duman, and Nalan Karadag, and Zeki Ongen, and Vural A Vural
Coronary artery calcification as an indicator of preclinical coronary artery disease.
January 1999, Radiographics : a review publication of the Radiological Society of North America, Inc,
Mine Kucur, and Bilgehan Karadag, and Ferruh K Isman, and Yusup Ataev, and Dursun Duman, and Nalan Karadag, and Zeki Ongen, and Vural A Vural
Plasma fibrinogen levels as an independent indicator of severity of coronary atherosclerosis.
June 1989, Atherosclerosis,
Mine Kucur, and Bilgehan Karadag, and Ferruh K Isman, and Yusup Ataev, and Dursun Duman, and Nalan Karadag, and Zeki Ongen, and Vural A Vural
Plasma homocysteine and the extent of atherosclerosis in patients with coronary artery disease.
August 1997, International journal of cardiology,
Mine Kucur, and Bilgehan Karadag, and Ferruh K Isman, and Yusup Ataev, and Dursun Duman, and Nalan Karadag, and Zeki Ongen, and Vural A Vural
Distribution of coronary atherosclerosis in patients with coronary artery disease.
January 2010, Heart and vessels,
Mine Kucur, and Bilgehan Karadag, and Ferruh K Isman, and Yusup Ataev, and Dursun Duman, and Nalan Karadag, and Zeki Ongen, and Vural A Vural
'Tendon xanthomas' as an indicator of premature coronary artery disease.
January 2015, Oxford medical case reports,
Mine Kucur, and Bilgehan Karadag, and Ferruh K Isman, and Yusup Ataev, and Dursun Duman, and Nalan Karadag, and Zeki Ongen, and Vural A Vural
Retinal arteriolar changes as an indicator of coronary artery disease.
October 1979, Archives of internal medicine,
Mine Kucur, and Bilgehan Karadag, and Ferruh K Isman, and Yusup Ataev, and Dursun Duman, and Nalan Karadag, and Zeki Ongen, and Vural A Vural
Vasoconstrictor activity of coronary sinus plasma from patients with coronary artery disease.
June 1987, Journal of the American College of Cardiology,
Mine Kucur, and Bilgehan Karadag, and Ferruh K Isman, and Yusup Ataev, and Dursun Duman, and Nalan Karadag, and Zeki Ongen, and Vural A Vural
Incidence of carotid artery atherosclerosis in patients with coronary artery disease.
January 1993, Angiology,
Mine Kucur, and Bilgehan Karadag, and Ferruh K Isman, and Yusup Ataev, and Dursun Duman, and Nalan Karadag, and Zeki Ongen, and Vural A Vural
Hyaluronidase activity in serum of patients with complicated atherosclerosis.
January 1976, Acta medica Polona,
Mine Kucur, and Bilgehan Karadag, and Ferruh K Isman, and Yusup Ataev, and Dursun Duman, and Nalan Karadag, and Zeki Ongen, and Vural A Vural
Serum sialic acid as an indicator of change in coronary artery disease.
February 1995, Metabolism: clinical and experimental,
Copied contents to your clipboard!